Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Department of Medicine, Baylor College of Medicine, and Methodist DeBakey Heart and Vascular Center, Houston, TX.
Diabetes Care. 2020 Jun;43(6):1200-1208. doi: 10.2337/dc19-2043. Epub 2020 Mar 11.
Incorporation of comorbidity burden to inform diabetes management in older adults remains challenging. High-sensitivity cardiac troponins are objective, quantifiable biomarkers that may improve risk monitoring in older adults. We assessed the associations of elevations in high-sensitivity cardiac troponin I (hs-cTnI) and T (hs-cTnT) with comorbidities and improvements in mortality risk stratification.
We used logistic regression to examine associations of comorbidities with elevations in either troponin (≥85th percentile) among 1,835 participants in the Atherosclerosis Risk in Communities (ARIC) Study with diabetes (ages 67-89 years, 43% male, 31% black) at visit 5 (2011-2013). We used Cox models to compare associations of high cardiac troponins with mortality across comorbidity levels.
Elevations in either troponin (≥9.4 ng/L for hs-cTnI, ≥25 ng/L for hs-cTnT) were associated with prevalent coronary heart disease, heart failure, chronic kidney disease, pulmonary disease, hypoglycemia, hypertension, dementia, and frailty. Over a median follow-up of 6.2 years (418 deaths), both high hs-cTnI and high hs-cTnT further stratified mortality risk beyond comorbidity levels; those with a high hs-cTnI or hs-cTnT and high comorbidity were at highest mortality risk. Even among those with low comorbidity, a high hs-cTnI (hazard ratio 3.0 [95% CI 1.7, 5.4]) or hs-cTnT (hazard ratio 3.3 [95% CI 1.8, 6.2]) was associated with elevated mortality.
Many comorbidities were reflected by both hs-cTnI and hs-cTnT; elevations in either of the troponins were associated with higher mortality risk beyond comorbidity burden. High-sensitivity cardiac troponins may identify older adults at high mortality risk and be useful in guiding clinical care of older adults with diabetes.
将合并症负担纳入指导老年人糖尿病管理仍然具有挑战性。高敏心肌肌钙蛋白是客观的、可量化的生物标志物,可能改善老年人的风险监测。我们评估了高敏心肌肌钙蛋白 I(hs-cTnI)和 T(hs-cTnT)升高与合并症的关系,并评估其对死亡率风险分层的改善作用。
我们使用逻辑回归分析了 1835 名参加动脉粥样硬化风险社区研究(ARIC)的糖尿病患者(年龄 67-89 岁,43%为男性,31%为黑人)在第 5 次就诊(2011-2013 年)时 hs-cTnI(≥第 85 个百分位数)或 hs-cTnT(≥25ng/L)升高与合并症之间的关系。我们使用 Cox 模型比较了高心脏肌钙蛋白与不同合并症水平下的死亡率之间的关系。
hs-cTnI(≥9.4ng/L)或 hs-cTnT(≥25ng/L)升高与冠心病、心力衰竭、慢性肾脏病、肺部疾病、低血糖、高血压、痴呆和衰弱等现患合并症有关。在中位随访 6.2 年(418 例死亡)期间,hs-cTnI 和 hs-cTnT 升高进一步分层死亡率风险,超过了合并症水平;hs-cTnI 或 hs-cTnT 升高和高合并症的患者死亡率最高。即使在合并症低的患者中,hs-cTnI 升高(危险比 3.0 [95%CI 1.7, 5.4])或 hs-cTnT 升高(危险比 3.3 [95%CI 1.8, 6.2])也与死亡率升高相关。
hs-cTnI 和 hs-cTnT 均反映了许多合并症;两种肌钙蛋白中任意一种升高与合并症负担以外的更高死亡率风险相关。高敏心肌肌钙蛋白可能识别出高死亡率风险的老年人,有助于指导老年糖尿病患者的临床治疗。